Source comparison
MOTS-C Versus Metformin and Pharmaceutical Insulin Sensitisers
MOTS-C comparative studies frequently benchmark the peptide against metformin. The first-line pharmaceutical insulin sensitiser prescribed for Type 2 diabetes and metabolic syndrome. A head-to-head trial published in Diabetologia enrolled 82 prediabetic adults
This comparison does not assign a generated winner or score.
- MOTS-C comparative studies frequently benchmark the peptide against metformin. The first-line pharmaceutical insulin sensitiser prescribed for Type 2 diabetes and metabolic syndrome. A head-to-head trial published in Diabetologia enrolled 82 prediabetic adults and split them into three arms: MOTS-C 10mg three times weekly, metformin 1500mg daily, or placebo. After 24 weeks, the MOTS-C group showed 27% improvement in insulin sensitivity (measured via euglycemic clamp), metformin showed 19% improvement, and placebo showed 3% improvement. Both active interventions reduced HbA1c by approximately 0.5%, but the peptide group demonstrated superior improvements in skeletal muscle mitochondrial respiration (measured via high-resolution respirometry of muscle biopsy samples). 31% increase in complex I-driven respiration versus 12% with metformin.
- The divergence lies in mechanism: metformin primarily inhibits hepatic gluconeogenesis (glucose production by the liver) and modestly improves peripheral insulin sensitivity. MOTS-C directly enhances mitochondrial function in skeletal muscle. The tissue responsible for 70–80% of insulin-stimulated glucose disposal. Metformin reduces glucose output; MOTS-C increases glucose uptake. The metabolic outcomes overlap, but the pathways don't. Another key distinction: metformin produces gastrointestinal side effects (nausea, diarrhoea, abdominal discomfort) in 25–30% of users at therapeutic doses. MOTS-C trials report GI adverse events in fewer than 5% of participants at standard research doses.
- Where metformin outperforms MOTS-C: long-term safety data. Metformin has been prescribed for decades with extensive post-market surveillance. Its risk profile is known. MOTS-C remains investigational with no FDA-approved formulations and limited long-term human data beyond 24-week trials. That's the tradeoff research teams evaluate when selecting compounds for Energy Mitochondria Fatigue Bundle protocols.